Zhifan Li,Yanan Gao,Qianhong Lu,Zheng Yin,Shuang Zhang,Wenjia Zhang,Yonggang Sui,Yanlu Xu,Jianjun Li,Kefei Dou,Jie Qian,Hong Qiu,Naqiong Wu

Abstract:Remnant cholesterol (RC) and nonhigh-density lipoprotein cholesterol (nonHDL-C) are key risk factors for atherosclerotic cardiovascular disease (ASCVD), with apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] also contributing to its residual risk. However, real-world population-based evidence regarding the impact of current clinical LDL-C-centric lipid-lowering therapy (LLT) on achieving RC and nonHDL-C goals, as well as on modifying residual CVD risk factors is limited.

The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study